The global cholangiocarcinoma therapeutics market is poised for moderate yet steady expansion, with projections indicating it will reach USD 994.8 million by 2035, up from USD 832.3 million in 2025, growing at a CAGR of 1.8%. This trajectory is fueled by a combination of medical advancements, increasing investments in rare cancer drug research, and the …